Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neovasculgen Surveillance in Peripheral Arterial Disease
NCT02369809Phase 4Completed
- Sponsor
- Artgen Biotech
- Start
- Sep 2012
- Primary completion
- Jan 2017
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 4 trial of neovasculgen in Peripheral Arterial Disease (PAD), sponsored by Artgen Biotech. Started Sep 2012; status: completed.
02
Drugs
neovasculgen
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02369809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369809.